Profile data is unavailable for this security.
About the company
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.
- Revenue in USD (TTM)428.00k
- Net income in USD-8.56m
- Incorporated1994
- Employees16.00
- LocationBioCardia Inc320 Soquel WaySUNNYVALE 94085United StatesUSA
- Phone+1 (650) 226-0123
- Fax+1 (650) 631-3731
- Websitehttps://www.biocardia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plus Therapeutics Inc (USA) | 5.51m | -13.23m | 9.43m | 20.00 | -- | -- | -- | 1.71 | -3.05 | -3.05 | 1.19 | -1.34 | 0.4336 | -- | -- | 275,450.00 | -104.14 | -59.18 | -- | -133.04 | -- | -- | -240.15 | -470.45 | -- | -4.17 | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Oncotelic Therapeutics Inc | 70.00k | -1.24m | 9.55m | 22.00 | -- | 0.7873 | -- | 136.39 | -0.0031 | -0.0031 | 0.0002 | 0.0299 | 0.0023 | -- | 3.69 | 3,181.82 | -5.02 | -25.03 | -11.26 | -48.76 | -- | -- | -2,147.66 | -1,692.93 | -- | -0.5167 | 0.5228 | -- | -- | -- | -255.12 | -- | -- | -- |
| Avalo Therapeutics Inc | 807.00k | -36.22m | 9.69m | 19.00 | -- | -- | -- | 12.01 | -63.82 | -63.82 | 0.3347 | -2.08 | 0.0122 | -- | 20.96 | 42,473.68 | -54.66 | -99.64 | -529.15 | -154.42 | 64.19 | 84.69 | -4,488.60 | -613.58 | -- | -- | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Kazia Therapeutics Ltd (ADR) | 15.37k | -13.94m | 9.84m | 12.00 | -- | 0.9173 | -- | 640.16 | -0.8458 | -0.8458 | 0.0008 | 0.3601 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Kintara Therapeutics Inc | 0.00 | -9.51m | 10.06m | 2.00 | -- | -- | -- | -- | -4.08 | -4.08 | 0.00 | 0.1071 | 0.00 | -- | -- | 0.00 | -131.55 | -220.94 | -185.60 | -329.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 40.24 | -- | 78.93 | -- |
| Check Cap Ltd | 0.00 | -17.57m | 10.12m | 85.00 | -- | 0.4273 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
| Forte Biosciences Inc | 0.00 | -35.76m | 10.23m | 11.00 | -- | 0.602 | -- | -- | -22.03 | -22.03 | 0.00 | 11.64 | 0.00 | -- | -- | 0.00 | -124.89 | -72.06 | -170.91 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Jaguar Health Inc | 10.19m | -35.67m | 10.26m | 49.00 | -- | 0.5139 | -- | 1.01 | -41.34 | -41.34 | 6.62 | 2.48 | 0.1793 | 0.231 | 7.56 | 207,857.10 | -63.73 | -95.29 | -110.34 | -163.54 | 79.79 | 67.28 | -355.51 | -522.28 | 1.60 | -3.45 | 0.6333 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Virax Biolabs Group Ltd | 156.42k | -6.73m | 10.31m | 17.00 | -- | 1.21 | -- | 65.89 | -3.35 | -3.35 | 0.078 | 2.09 | 0.0205 | 3.51 | -- | 9,201.18 | -88.11 | -- | -91.88 | -- | 32.34 | -- | -4,308.35 | -- | 25.58 | -227.16 | 0.0418 | -- | 1,727.34 | -- | -23.38 | -- | -- | -- |
| Cell MedX Corp | 0.00 | -142.49k | 10.40m | 0.00 | -- | -- | -- | -- | -0.0021 | -0.0021 | 0.00 | -0.0028 | 0.00 | -- | -- | -- | -190.76 | -703.78 | -- | -- | -- | 84.03 | -- | -2,996.54 | -- | -4.35 | -- | -- | -100.00 | -- | 71.22 | -- | -- | -- |
| BioCardia Inc | 428.00k | -8.56m | 10.44m | 16.00 | -- | -- | -- | 24.38 | -5.40 | -5.40 | 0.2636 | -0.9233 | 0.0923 | -- | 6.85 | 26,750.00 | -184.48 | -107.34 | -1,075.25 | -154.17 | -- | -- | -1,999.77 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Enzon Pharmaceuticals Inc | 26.00k | 314.00k | 10.45m | 0.00 | 33.29 | 3.44 | -- | 401.90 | 0.0042 | 0.0042 | 0.0004 | 0.6277 | 0.0006 | -- | -- | -- | 3.39 | -0.8654 | 3.42 | -0.8851 | -- | -- | 6,111.54 | -159.43 | -- | -- | 0.00 | -- | -100.00 | -- | 106.71 | -55.86 | -- | -- |
| Portage Biotech Inc | 0.00 | -71.08m | 10.71m | 7.00 | -- | 4.27 | -- | -- | -68.81 | -68.81 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -137.29 | -30.53 | -143.21 | -40.02 | -- | -- | -- | -- | -- | -- | 0.02 | -- | -- | -- | 27.98 | -- | -- | -- |
| GlycoMimetics Inc | 10.00k | -39.11m | 10.96m | 35.00 | -- | 0.5464 | -- | 1,096.23 | -0.6071 | -0.6071 | 0.0002 | 0.3111 | 0.0002 | -- | 0.0685 | 285.71 | -90.71 | -43.60 | -103.87 | -47.82 | -- | -- | -391,132.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Kiora Pharmaceuticals Inc | 16.02m | 2.67m | 11.04m | 12.00 | -- | 0.3337 | 4.09 | 0.6894 | -7.76 | -7.76 | 6.61 | 11.14 | 0.5279 | -- | 7.16 | 1,335,000.00 | 10.54 | -70.52 | 11.20 | -81.86 | -- | -- | 19.98 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to BioCardia Inc's reporting currency: US Dollar USD
4.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Susquehanna Financial Group LLLPas of 30 Jun 2024 | 44.56k | 2.10% |
| Geode Capital Management LLCas of 30 Jun 2024 | 13.02k | 0.61% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 12.62k | 0.59% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Jun 2024 | 11.19k | 0.53% |
| Tower Research Capital LLCas of 30 Jun 2024 | 3.04k | 0.14% |
| Pingora Partners LLCas of 30 Jun 2024 | 1.04k | 0.05% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 30 Jun 2024 | 435.00 | 0.02% |
| Global Retirement Partners LLCas of 30 Jun 2024 | 411.00 | 0.02% |
| Vanguard Global Advisers LLCas of 30 Jun 2024 | 268.00 | 0.01% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 30.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
